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ABSTRACT 
We conducted an epigenome-wide association study meta-analysis (meta-EWAS) on blood pressure (BP) 
in 4,820 individuals of European and African ancestry aged 14-69. Genome-wide DNA methylation data 
from peripheral leukocytes were obtained using the Infinium HumanMethylation450k BeadChip. The 
meta-EWAS identified 39 BP-related CpG sites with p<1×10-5. In silico replication in the CHARGE 
consortium of 17,010 individuals validated 16 of these CpG sites. Out of the 16 CpG sites, 13 showed 
novel association with BP.  Conversely, out of the 126 CpG sites identified as being associated (p<1x10-7) 
with BP in the CHARGE consortium, 21 were replicated in the current study. Methylation levels of all the 
34 CpG sites that were cross-validated by the current study and the CHARGE consortium were heritable 
and 6 showed association with gene expression. Furthermore, 9 CpG sites also showed association with 
BP with p<0.05 and consistent direction of the effect in the meta-analysis of the Finnish Twin Cohort 
(199 twin pairs and 4 singletons; 61% monozygous) and the Netherlands Twin Register (266 twin pairs 
and 62 singletons; 84% monozygous). Bivariate quantitative genetic  modeling of the twin data showed 
that a majority of the phenotypic correlations between methylation levels of these CpG sites and BP 
could be explained by shared unique environmental rather than genetic factors, with 100% of the 
correlations of systolic BP with cg19693031 (TXNIP) and cg00716257 (JDP2) determined by 
environmental effects acting on both systolic BP and methylation levels.  
  
INTRODUCTION 
Essential hypertension (EH) is a major health problem with global proportions. A report in the Lancet1 
estimated that in 2015 there were 1.13 billion people living with high blood pressure (BP) worldwide. 
While many pathways involved in the development of EH and corresponding treatment options have 
been discovered, the elevated blood pressure (BP) of 16 million hypertensive patients remains 
uncontrolled2, indicating the need for further understanding of its pathogenesis. Epigenetics has 
recently been suggested as a massive regulatory machine that cannot be ignored in searching for the 
molecular understanding of EH 3, 4. In fact, it may explain the late onset, progressive and quantitative 
nature of this disease better than variations in DNA sequence.   
        Epigenetic alterations of the genes of the renin-angiotensin-aldosterone system, a hormone system 
that is integral to the physiological regulation of BP, have been extensively tested in hypertensive animal 
models, providing one line of substantial evidence on the involvement of epigenetic regulation in the 
development of EH 5. A recent, genome-wide, peripheral blood DNA methylation study in human by the 
CHARGE consortium6, including a discovery and a replication panel, identified 13 CpG sites in or next to 
8 genes that were differentially methylated in relation to BP. A methylation risk score based on these 13 
CpG sites explained 1.4% and 2.0% of the inter-individual variation in systolic and diastolic BP, 
respectively. Expanding the methylation risk score to include 126 CpG sites that were Bonferroni 
significant (p<1x10-7) in the overall meta-analysis did not explain additional phenotypic variance, 
indicating the need for further replication. Moreover, unlike sequence variation, epigenetic variation is 
influenced both by inherited and environmental factors7, 8. This is illustrated by the fact that 30-100% of 
the DNA methylation levels of the 13 BP-associated CpG sites described above is explained by heritable 
factors as estimated by the family data of the Framingham Heart Study 6. However, the extent to which 
the link between BP and DNA methylation signatures is driven by inherited vs. environmental factors has 
not been investigated. 
        In the present meta-EWAS in leukocytes of 4,820 individuals of European (EA) and African ancestry 
(AA) aged 14-69, we first identified new DNA methylation signals associated with BP and validated these 
signals in the CHARGE consortium6; next we attempted to replicate the 126 previously identified signals 
by the CHARGE consortium 6 in our own meta-EWAS data; third we conducted twin modeling to 
estimate the heritability of DNA methylation correlated with BP, and finally we assessed the genetic and 
environmental sources of the correlation between DNA methylation and BP (Figure S1).  
 
METHODS 
Data availability 
This study involves multiple cohorts. The genome wide DNA methylation data that support the findings 
of this study are available from the study PI of each cohort upon reasonable request and with 
permission of the Institutional Review Board of the universities where the participating cohort locates. 
 
Study Populations 
The discovery panel included 4820 individuals of EA and AA ancestries from 12 adult cohorts (average 
age ranges from 27.3 to 63.5 years old) and 2 youth cohorts (average age 16.2 and 17.7 years old) (Table 
1). Details of each cohort are provided in the Supplemental Data. All studies obtained written informed 
consent from participants and were approved by local institutional review boards and ethics committees. 
 
Blood Pressure Measurements  
For all the cohorts, BP was measured after a period of rest and an average of 3 sequential readings was 
used as the phenotype for each analysis.  For 3 cohorts (GSH, EpiGO and LACHY), BP was measured in a 
supine position, while for the other 11 cohorts, BP was measured in a sitting position.  With the 
exception of the NTR cohort for which BP was measured within ±2 years from the methylation 
measurement, all the cohorts had BP measured concurrently with the collection of peripheral 
leukocytes for DNA methylation profiling.  If antihypertensive medication was used, 15mmHg and 
10mmHg were added to the measured SBP and DBP levels, respectively9. 
 
DNA Methylation Profiling  
For all cohorts, genome-wide DNA methylation data were obtained from peripheral blood using the 
Illumina Infinium Human Methylation 450K Beadchip (Illumina Inc.).  A detailed description on 
preprocessing and quality control steps for each cohort is provided in the Supplementary Data. For all 
cohorts, white blood cell sub-populations were estimated using the approach described by Houseman et 
al.10.  
 
Cohort Level Association Analysis 
For cohorts only including unrelated subjects, a linear regression model was used to estimate the 
associations between DNA methylation (i.e. β values) and BP with methylation levels used as dependent 
variables adjusting for age, sex, ancestry (in samples including EAs and AAs), BMI, and white blood cell 
sub-populations. For cohorts including related subjects, a linear mixed effect model was used to account 
for sample relatedness.  
 
Meta-Analyses & Cross Validation 
Meta-analysis across the 14 cohorts was conducted using METAL11 by converting the direction of effect 
and p-value observed in each cohort into a signed Z-score. CpG sites with p≤1×10-5 for either SBP or DBP 
were selected for replication in the CHARGE consortium (n=17,010). Replication was defined as 
consistent direction of the β-coefficient and FDR<0.05. Conversely, we also checked whether we could 
replicate the 126 CpG sites for BP identified in the overall meta-analysis of the CHARGE consortium in 
our own meta-EWAS results. Replication was again defined as a consistent direction of the β-coefficient 
and FDR<0.05.   
 
Percent Variance Explained 
Percent variance explained by the cross-validated BP associated CpG sites was calculated in the Lifelines 
DEEP cohort. To avoid overestimation of percent variance explained, this cohort was not included in the 
Meta-analysis. Percent variance explained by the cross-validated BP associated CpG sites is reported as 
the change in the adjusted R2 from the model including these CpG sites compared to the model only 
including covariates (i.e. age, gender and BMI).   
 
Pathway Analysis 
Pathway enrichment analysis was conducted on the meta-analysis results of the genome-wide DNA 
methylation data using gene set enrichment analysis (GSEA)12. GSEA was performed on an unfiltered, 
ranked list of genes (ranked by the p values without consideration of directions), and a running-sum 
statistic was used to determine the enrichment of a priori defined gene sets (pathways) based on the 
gene ranks. All gene ontology biological process categories (c5.bp.v5.1) were assessed for enrichment at 
FDR<0.05.  The CpG site showing the most significant p value within a gene was used to represent the 
DNA methylation level of the gene.   
 
Associations of DNA Methylation and Gene Expression 
Association tests of the cross-validated BP-associated CpGs (Figure S1) with transcripts that were 
located within 500kb distance of the corresponding CpGs were performed in the 391 individual twins of 
the Finnish Twin Cohort for whom both DNA methylation and gene expression data were available. 
Gene expression data were obtained using the Illumina Human HT-12 V4 expression Beadchip (Illumina, 
Inc, San Diego, CA) 13. Linear mixed effects regression models were used with gene expression as the 
dependent variable, DNA methylation as the independent variable, age, sex, and BMI as fixed effects, 
and family as a random effect. An FDR < 0.05 was defined as significant association between DNA 
methylation and gene expression. BP associated gene expressions were defined as genes with their 
expression levels showing significant association with either SBP or DBP at p < 0.05. 
 
Genetic and Environmental Determinants of DNA Methylation Associated with BP  
For all the cross-validated BP associated CpG sites (Figure S1), we estimated the relative contributions of 
genetic and environmental factors to the variance of DNA methylation levels in the Finnish Twin Cohort 
and the Netherlands Twin Register using the R package OpenMx14, 15. Before analysis, age, sex and BMI 
were regressed out, and the DNA methylation residuals were used in the model fitting. Details of this 
univariate structural equation model for twin data (Figure S2) were described in a previous study 13. In 
short, the model allows separation of the observed phenotypic variance into its genetic and 
environmental variance components including additive genetic variance (A), common environmental 
variance shared by a twin pair (C), and unique environmental variance specific to individuals (E). The 
monozygotic twins of each pair (MZ twins) have identical genome sequences, while dizygotic twins (DZ 
twins) share 50% of their segregating alleles. Shared environmental factors are exposures and 
experiences that affect co-twins similarly on average irrespective of zygosity, while unique 
environmental factors are the effects not shared by cotwins and include measurement error. 
Significance tests of individual variance components (A or C) were conducted by comparing full models 
with sub-models constraining paths from latent variables to trait values (a, c) to 0 using a chi-square test; 
as E contains measurement error, the significance of E is not tested. Statistical significance was defined 
as p < 0.05. The analysis was conducted in each twin cohort separately, then a meta-analysis across the 
two twin cohorts (FTC and NTR) was performed to estimate the mean heritability (h2) using the Meta 
package in R 16. Following the approach described by Asefa et al. 17, each h2 was transformed using a 
logit function 18 and a random-effects model was used for the meta-analysis. The pooled h2 (weighted by 
sample size) and 95% confidence intervals (CIs) were back-transformed. Heterogeneity between studies 
was quantified with Cochran’s Q test and the I2-statistic 19. 
Sources Underlying the Associations between DNA Methylation and BP 
For all the cross-validated BP associated CpG sites (Figure S1), we checked whether they were also 
significantly associated with BP in the meta-analysis of the Finnish Twin Cohort and the Netherlands 
Twin Register, i.e., a consistent direction of the β-coefficients and p<0.05. For those CpG sites 
significantly associated with BP in the meta-analysis of these two twin cohorts, we conducted bivariate 
structural equation modelling to test the extent to which the link between BP and DNA methylation was 
driven by genetic or environmental factors. Details of this model (Figure S3) have been described 
previously13. Briefly, the variation of DNA methylation and the variation of BP were decomposed into A, 
C, and E variance components. The bivariate model allows determination of the sources of the observed 
covariance between DNA methylation and BP by using a sequence of sub-models that test which genetic, 
shared environmental or unique environmental paths from DNA methylation to BP can be set to 0. For 
example, in Figure S3, if a21 (genetic path from DNA methylation to BP) cannot be set to 0, it means 
there is overlap between the genetic factors influencing DNA methylation and BP. The model further 
allows calculation of genetic and environmental correlations between the traits. Similar to the univariate 
analysis, the bivariate analysis was conducted in each twin cohort separately, then a meta-analysis was 
conducted to determine the genetic and environmental contributions to the correlation between DNA 
methylation and BP. Briefly, for each cohort, genetic (rg) and environmental (re) correlations were 
calculated based on the variance/covariance matrix estimated from the bivariate twin modeling (Figure 
S3). The genetic contribution to the observed phenotypic correlation (rph) is a function of the heritability 
estimates of the two phenotypes and the rg between them, i.e. �ℎ𝑀𝑀2 × 𝑟𝑟𝑔𝑔 × �ℎ𝐵𝐵𝐵𝐵2 . Similarly, the 
environmental contribution to rph is equal to �𝑒𝑒𝑀𝑀2 × 𝑟𝑟𝑒𝑒 × �𝑒𝑒𝐵𝐵𝐵𝐵2 . Then a random-effects model was used 
to estimate the meta-genetic and environmental contributions respectively with the 95% CIs.   
RESULTS 
The general characteristics of the study participants are listed in Table 1. A total of 4820 individuals were 
included from 14 cohorts with a wide range of mean SBP and DBP values. The prevalence of 
antihypertensive medication use also varied among the cohorts.   
        Our meta-analysis identified 39 CpG sites associated with SBP or DBP at p<1×10-5 (Manhattan and 
QQ plot, Supplementary Data Figure S4 and Figure S5; Table S1) with two CpG sites showing p<1×10-7.  
Out of these 39 CpG sites, the heterogeneity test across the cohorts reached significance (P<0.05) for 
five sites (cg06500161, cg00508575, cg19693031, cg12555233 & cg02711608, Supplementary Data 
Table S1). Further sensitivity tests by ancestry (EA vs AA) or age (adult cohorts vs. youth cohorts) did not 
support the heterogeneity being due to ancestry or age. Sixteen out of the 39 CpG sites including the 
three showing heterogeneity (cg06500161, cg00508575, & cg19693031) could be replicated (FDR<0.05) 
in the CHARGE consortium (Table 2).  Of the 16 replicated CpG sites, only three (cg02711608, 
cg19693031, cg08857797) have previously been reported to be associated with BP (highlighted in gray 
in Table 2) and the other 13 were novel signals.  Conversely, of the 126 CpG sites found to be associated 
with BP by the CHARGE consortium in the overall sample, 91 sites showed the same direction of effect in 
our meta-analysis with 21 sites having FDR < 0.05 (Table 3).  These 21 CpG sites included the three CpG 
sites previously reported to be associated with BP (highlighted in gray in Table 3). In total, 34 CpG sites 
were cross-validated to be associated with BP by the current meta-analysis and the CHARGE consortium. 
To assess the impact of antihypertensive medication use, we stratified the meta-analysis of these 34 
CpG sites by medication use and provide the results in Supplementary Data Table S2. In the individuals 
reporting no use of antihypertensive medications, the directions of the effects of all the CpG sites 
remained the same as for the overall sample with 27 out of the 34 retaining their significant associations 
(p<0.05) with BP, rendering it highly unlikely that the differentially methylated CpG sites we identified 
reflect drug treatment effects.   
        Inclusion of 33 out of the 34 CpG sites (cg02711608 was filtered out in the quality control step of 
the Lifelines DEEP cohort) explained an additional 3.31% and 3.99% of the interindividual variation in 
SBP and DBP, respectively, beyond the traditional BP covariates of age, gender and BMI in an additional 
sample from the Lifelines cohort (the Lifelines DEEP cohort, n=601) not included in the current meta-
analysis. Details of this cohort are provided in the Supplemental Data. Using the Lifelines DEEP cohort, 
we further explored whether these 33 CpG sites were individually or collectively associated with EH. A 
total of 102 out of the 601 (16.97 %) participants were classified as having EH (i.e., SBP≥140 mmHg, or 
DBP≥90 mmHg, or taking antihypertensive medication). Out of the 33 CpG sites, 4 CpG sites 
(cg12593793, cg11376147, cg21766592 and cg06500161) were individually associated with EH with 
p<0.05 in the expected direction (Supplementary Data Table S3). Collectively, adding these 33 CpG sites 
in the model with age, gender and BMI as covariates increased Nagelkerke’s pseudo R2 from 34.3% to 
47.7%.  
        Of the 34 CpG sites, the methylation levels of six sites were significantly associated with the 
expression of five genes in cis analysis (FDR <0.05) (Table 4). The methylation-gene expression 
associations did not differ by medication use. For all the CpG sites, increased methylation was associated 
with decreased gene expression (Supplementary Data Figure S6).  Furthermore, expression of two genes 
(i.e. ABCG1 and LMNA) showed significant association with BP. For both genes the direction of the 
association between CpG methylation and gene expression was as expected based on the association of 
CpG methylation and BP. For example, the methylation level of cg06500161 was negatively associated 
with ABCG1 gene expression and positively associated with SBP. This was consistent with the negative 
association between ABCG1 gene expression and SBP.  
        The pathway analyses yielded significant (FDR <0.05) enrichment of four biological process 
pathways for SBP-related DNA methylation changes, and six for DBP-related methylation changes in 
peripheral leukocytes (Supplementary Data Table S4). The primary pathway identified by the CHARGE 
consortium6, the transport of neutral amino acids, also showed borderline significance in the current 
enrichment analyses for both SBP (FDR=0.060) and DBP (FDR=0.074).  
        The cohort-level results of the univariate structural equation model analysis on the DNA 
methylation levels of the 34 cross-validated CpG sites are listed in Table S5.   For all the CpG sites, the 
best fitting models were AE models, with heritability estimates ranging from 31% to 83% in the Finnish 
Twin Cohort and 19% to 81% in the Netherlands Twin Register. The remaining part of the variation for 
DNA methylation of these CpG sites was attributable to environmental influences that are unique to the 
individual. Table 5 lists the heritability of the 34 CpG sites from the meta-analysis. The heritabilities 
ranged from 31% to 78%.  
        Of the 34 implicated CpG sites, the methylation level of 9 CpG sites showed significant association 
with BP in the meta-analysis of the Finnish Twin Cohort and the Netherlands Twin Register (Table 6). For 
these 9 sites, we estimated the relative contributions of genetic and environmental factors to the 
association between DNA methylation and BP.  Given that the AE model has generally been the best 
fitting model in previous twin studies of BP 20, which was again confirmed in the current study, the 
bivariate modeling was conducted using the AE model both for DNA methylation and BP. The cohort-
level results are listed in Table S6 and the meta-analysis results are listed in Table 6.  For the association 
of cg19693031 in the TXNIP gene and cg00716257 in the JDP2 gene with SBP, the meta-analysis showed 
that the correlation due to the environmental contribution cannot be set to 0 while the genetic 
contribution can be set to 0, suggesting that the phenotypic correlation is determined by unique 
environmental factors in common to the two traits. Similar trends were observed for the association of 
cg11468085 with SBP and cg19693031 with DBP. For the associations of the other CpG sites with BP, 
both genetic and environmental contributions can be set to 0, indicating a larger sample size is needed 
to increase the power to distinguish the relative contributions of genetic and environmental factors to 
the observed phenotypic correlations. 
 
DISCUSSION 
In this epigenome-wide association study, we identified 13 novel CpG sites associated with BP and 
replicated 21 CpG sites previously identified in the overall meta-analysis of the CHARGE consortium6. We 
also showed that DNA methylation levels from 6 of the 34 cross-validated CpG sites were associated 
with gene expression. Although all of the 34 CpGs were heritable (31-78%), further bivariate twin 
modeling analyses in the Finnish Twin Cohort and the Netherlands Twin Register suggested that, among 
the 9 CpG sites that were associated with BP, the correlations of cg19693031(TXNIP) and 
cg00716257(JDP2) with SBP were primarily attributable to  environmental factors that affect both traits, 
rather than genetic factors.  
        The 13 novel CpG sites that were associated with BP were annotated to 10 genes. Among these, 
only ABCG1 and ATP2B1 have previously been implicated in hypertension. For example, newly 
diagnosed hypertensive patients have been shown to have lower ABCG1 expression in peripheral blood 
monocytes in comparison with normotensive controls21. This is consistent with our results in which we 
also observed that peripheral leukocyte ABCG1 expression was negatively correlated with both SBP and 
DBP levels. Several genetic variants in ATP2B1 have been associated with BP and hypertension in  
multiple GWA studies22-24, and animal studies25 have demonstrated that mice lacking ATP2B1 in vascular 
smooth muscle cells had higher BP than wild type mice. In the current study, we observed higher 
methylation level of cg00508575 in ATP2B1 associated with higher SBP level; however, the methylation 
status of this CpG site was not associated with ATP2B1 expression levels in peripheral blood leukocytes. 
Further studies in other tissues such as vascular smooth muscle cells would be needed to clarify the 
functional role of this CpG site.  The potential involvement of the other 8 genes in the pathogenesis of 
hypertension has not been directly addressed in the literature although some evidence is available on 
their involvement in cardiovascular diseases. For example, TACC1 has been linked to inappropriate 
smooth muscle and endothelial cell proliferation in pulmonary arterial hypertension 26. Several genome-
wide association studies 27, 28 have reported variants in DAB21P, which encodes an inhibitor of cell 
growth and survival, that were associated with abdominal aortic aneurysm and atherosclerotic vascular 
diseases. ALDH3B2, encoding one member of the ALDH family of proteins that play a role in cell 
proliferation, differentiation, and responsiveness to environmental stress., has been suggested as a 
candidate gene for bisoprolol (a Beta blocker) responsiveness 29.  CpG sites in MAN2A2 have been 
associated with fasting insulin 30. Further experimental validation of the role of these genes in BP 
regulation is warranted. 
        Similar to the CHARGE consortium6 which involved cohorts from different ancestries (European, 
African American, and Hispanic) and a broad age range (18-80 years), the current study also included 
individuals from European and African American ancestry with an age range of 14-69 years.  The fact 
that the signals could be cross-validated between these two studies, and that both studies showed the 
effect of the majority of BP related CpG sites to be homogeneous across the cohorts, ancestral groups, 
and different age groups, indicates that these BP-related CpG sites may be ethnicity- and age- 
independent. However, a clearer picture of the role of DNA methylation in the pathogenesis of EH in 
various age and population groups will require even larger EWASs spanning multiple age ranges and 
ancestry groups. 
        Interestingly, the majority of the 34 cross-validated CpG sites have been linked with other metabolic 
phenotypes including obesity, lipids, CRP, insulin resistance and type 2 diabetes by previous epigenome-
wide association studies (Supplementary Data Table S7), indicating that DNA methylation may be one of 
the common factors related to the concurrence of multiple metabolic abnormalities. Indeed, 
epigenome-wide association studies have identified several CpG sites whose DNA methylation levels are 
associated with metabolic syndrome (MetS) including cg00574958 in the CPT1A gene31 and cg06500161 
in the ABCG1 gene32.  ABCG1 cg06500161 has also been reported to be associated with fasting insulin 33, 
blood lipids34, adiposity traits 35, 36 and type 2 diabetes 37, 38. In the current study we observed for the first 
time that a higher methylation level of cg06500161 was also associated with higher BP levels.  Taken 
together, these studies show that ABCG1 cg06500161 is associated with each MetS component, though 
the causal direction of these associations has not been determined. Furthermore, although the other 
components of MetS can be viewed as consequences of obesity, the associations of these CpG sites with 
these MetS components are independent of obesity. Future studies are warranted with multivariate 
analyses targeting multiple metabolic traits to disentangle the mechanisms involved in the association of 
DNA methylation with MetS and its components.  
        Unlike genetic sequence variants, epigenetic variation is influenced by both genetic and 
environmental factors7, 8. We first quantified the genetic and environmental sources of the variation in 
the 34 cross-validated BP associated CpG sites and confirmed that the variance of all these 34 CpG sites 
was indeed determined by both genetics (31-78%) and environment (22-69%). Since BP is also a 
heritable trait, an interesting question is to what extent the link between BP and DNA methylation is 
driven by genetic or environmental factors in common to the two traits. We tried to answer this 
question using the Finnish Twin Cohort and the Netherlands Twin Register by conducting a bivariate 
twin modeling analysis on BP and the 9 CpG sites which showed association with BP in the meta-analysis 
of these two cohorts.  Surprisingly, we observed that 100% of the correlations of BP with 
cg19693031(TXNIP) and cg00716257(JDP2) could be attributed to environmental factors in common to 
the two traits rather than genetic factors, despite evidence for high heritability of both methylation at 
those CpG sites and SBP. The apparent lack of shared genetic component indicates that the link between 
the methylation level of these two CpG sites and BP may be driven primarily by environmental 
conditions; the relatively modest sample size should be recognized however, and further confirmation is 
needed.   
        Our study has several limitations. First, it is cross-sectional, thus making it impossible to discern the 
temporal order between BP and DNA methylation. Second, the bivariate twin modeling analysis was 
only conducted in the Finnish Twin Cohort and the Netherlands Twin Register which included about 
1000 twins. An even larger sample size is required to tease out reliably the relative contribution of 
genetic or environmental factors to the associations of BP with DNA methylation. Third, we did not 
conduct in vitro and in vivo functional studies to confirm the impact of these CpG sites on gene 
expression and subsequently on blood pressure, which is warranted for future research.  
        In conclusion, we identified 13 novel CpG sites associated with BP, and replicated several previously 
identified signals.  These newly identified signals may aid in annotating the future gene findings by 
providing a potential molecular mechanism for BP regulation. Our study further provides new insights 
into the genetic and environmental sources of BP related DNA methylation signatures as well as their 
associations with BP. The identification of shared unique environmental factors rather than genetic 
factors between BP and DNA methylation of TXNIP and JDP2 indicates that the environment plays a 
significant role in creating an association between DNA methylation signatures and BP.  
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Table 1. General characteristics of the study cohorts  
 
BHS : the Bogalusa Heart Study; GSH: the Georgia Stress and Heart study; DILGOM: the DIetary, Lifestyle, and Genetic determinants 
of Obesity and Metabolic syndrome Study; ETS: the Emory Twin Study; EGCUT: the Estonian Genome Center of the University of 
Tartu; FTC: the Finnish Twin Cohort; HBCS: the Helsinki Birth Cohort Study; JHS: the Jackson Heart Study; Lifelines: the Lifelines 
Cohort Study; NTR: the Netherlands Twin Register; PREVEND: Prevention of REnal and Vascular ENd stage Disease study; YFS: the 
Young Finns Study; EpiGO: the EpiGenetic basis of Obesity induced cardiovascular disease and type 2 diabetes study; and LACHY: the 
Lifestyle, Adiposity, and Cardiovascular Health in Youth study. 
1) EA: European Ancestry; AA: African American.  
Cohorts N Race 1 Age, years 
Mean (SD)  
Female
, % 
BMI, kg/m2 SBP, mmHg DBP, mmHg HTN4, % AHT5, % 
Adult cohort          
BHS 968 EA, AA2  43.2(4.5) 56.5 30.8(7.5) 127.3(23.6) 81.2(14.6) 36.9 26.9 
GSH 480 EA, AA3  27.3(3.5) 52.4 29.9(8.2) 114.9(13.3) 66.6(8.81) 9.39 4.80 
DILGOM 512 EA 51.9(13.7) 53.7 26.9(4.8) 143.3(16.9) 83.4(10.0) 49.1 37.5 
ETS 218 EA 55.7(3.4) 0 29.4(4.7) 135.66(18.4) 84.8(11.8) 56.3 34.4 
EGCUT(Asthma) 173 EA 26.2(6.9) 64.2 22.8(3.0) 116.7(12.0) 73.2(9.4) ---6 ---6 
EGCUT (Young_Old) 100 EA 52.7(23.7) 52.0 26.7(5.1) 129.1(19.1) 79.6(10.4) ---6 ---6 
FTC 402 EA 62.3(3.7) 59.3 26.9(4.9) 150.2 (18.6) 87.8(11.0) 58.4 43.5 
HBCS 159 EA 63.5(2.8) 0 27.5(3.8) 148.1(19.0) 91.0(10.3) 75.0 44.7 
JHS 96 AA 38.4(4.3) 50 33.9(7.1) 127.8(23.7) 81.5(14.5) 50.0 34.3 
Lifelines 150 EA 50.3(10.5) 58.7 28.0(5.1) 124.4(12.0) 74.1(8.60) 10.0 0.00 
NTR 5967 EA 29.4(10.5)8 66.1 23.6(3.6)8 126.0(14.7) 76.3(10.5) 17.8 1.34 
PREVEND 307 EA 46.7(10.0) 39.7 27(4.6) 131.1(20.8) 76.2(11.2) 48.5 19.5 
YFS 188 EA 44.0(3.3) 38.8 26.3(4.4) 119.1(13.2) 73.2(9.5) 9.57 5.30 
Youth cohort          
EpiGO 188 AA 17.7(1.7) 48.4 29.3(11.5) 114.8(15.1) 63.8(7.7) 9.57 0.00 
LACHY 283 AA 16.2(1.3) 50.0 24.1(5.6) 112.9(10.1) 61.4(6.0) 3.53 0.00 
2) For BHS, there are 70.3% EA and 29.7% AA.  
3) For GSH, there are 52.5% EA and 47.5% AA.  
4) HTN: hypertension; HTN definition for adults: SBP≥140mmHg or DBP≥90mmHg or on antihypertensive medication; HTN definition 
for youth: SBP≥95th or DBP≥95th percentile for age, sex and height. 
5) AHT, antihypertensive treatment. 
6) Only medication adjusted BP data were available. 
7) This dataset included 499 MZ and 95 DZ twins as well as 2 spouses of twins. The 2 spouses of twins were excluded in the analyses 
only involving twins. 
8) Age and BMI at blood sampling time. 
 
  
Table 2. CpG sites showing association with BP in our analysis with p <1E-05 and replicated by CHARGE consortium with FDR<0.05 
Probe ID Chr. Position Gene 
SBP   DBP 
META 
 
CHARGE 
 
META 
 
CHARGE 
Direction* p 
 
Direction* P 
 
Direction* p 
 
Direction* p 
cg19693031 1 145441552 TXNIP - 2.18E-07  - 3.10E-29  - 4.65E-05   - 1.80E-14 
cg01343041 2 24397787 C2orf84 + 4.21E-07  + 2.30E-02  + 1.01E-04  + 5.74E-01 
cg19695041 8 38615330 TACC1 - 6.26E-06  - 4.45E-05  - 3.36E-02  - 3.26E-03 
cg13696706 9 124396830 DAB2IP + 9.83E-08  + 3.95E-03  + 1.16E-03  + 7.90E-01 
cg11468085 11 67435577 ALDH3B2 + 4.16E-06  + 1.75E-04  + 1.38E-04  + 2.27E-02 
cg00508575 12 90050967 ATP2B1 + 6.47E-06  + 1.44E-03  + 9.20E-04  + 1.63E-01 
cg05248321 14 20898128 KLHL33 + 7.01E-07  + 1.68E-05  + 1.88E-03  + 1.86E-03 
cg02003183 14 103415882 CDC42BPB + 3.66E-07  + 5.56E-07  + 1.54E-03  + 3.09E-02 
cg12555233 15 91455366 MAN2A2 + 2.74E-06  + 6.25E-03  + 3.50E-03  + 2.97E-02 
cg07558761 16 87866696 SLC7A5 + 8.83E-07  + 1.46E-05  + 1.71E-03  + 3.37E-04 
cg07021906 16 87866833 SLC7A5 + 1.38E-06  + 1.65E-06  + 3.37E-03  + 5.73E-03 
cg04583842 16 88103117 BANP + 5.54E-09  + 4.16E-03  + 2.99E-06  + 8.28E-01 
cg08857797 17 40927699 VPS25 + 9.64E-06   + 3.60E-10   + 4.98E-05   + 2.30E-06 
cg02711608 19 47287964 SLC1A5 - 7.48E-06   - 2.00E-21   - 1.41E-03   - 4.30E-10 
cg06500161 21 43656587 ABCG1  + 5.69E-06  + 1.01E-04  + 5.06E-05  + 1.01E-03 
cg01820192 21 44869762 C21orf125 + 6.44E-06   + 1.66E-02   + 3.96E-02   + 4.75E-02 
* “+” indicates that DNA methylation levels increase with BP increase. “-“indicates that DNA methylation levels decrease with BP 
increase. 
CpG sites previously reported by the CHARGE consortium are highlighted in gray.   
 
  
 
* “+” indicates that DNA methylation levels increase with BP increase. “-“indicates that DNA methylation levels decrease with BP 
increase. 
CpG sites that overlapped between Table 3 and Table 2 are highlighted in gray.   
Direction* p Direction* p Direction* p Direction* p
cg18933331 1 110186418 Intergenic - 4.80E-09 - 7.64E-03 - 2.40E-08 - 1.17E-02
cg16246545 1 120255941 PHGDH - 1.20E-22 - 4.11E-04 - 1.10E-09 - 4.34E-04
cg14476101 1 120255992 PHGDH - 2.70E-34 - 4.27E-05 - 2.10E-21 - 2.31E-04
cg19693031 1 145441552 TXNIP - 3.10E-29 - 2.18E-07 - 1.80E-14 - 4.65E-05
cg19266329 1 145456128 Intergenic - 1.90E-12 - 3.61E-03 - 5.70E-05 - 2.22E-01
cg24955196 1 154982621 ZBTB7B + 5.00E-08 + 8.28E-04 + 6.00E-06 + 5.09E-02
cg12593793 1 156074135 Intergenic - 2.60E-12 - 3.22E-03 - 3.00E-07 - 7.49E-02
cg18119407 2 201980504 CFLAR - 2.00E-09 - 7.10E-03 - 4.40E-05 - 4.51E-03
cg06690548 4 139162808 SLC7A11 - 1.60E-32 - 1.52E-05 - 7.90E-26 - 2.47E-05
cg18120259 6 43894639 LOC100132354 - 2.20E-21 - 5.58E-03 - 8.90E-14 - 4.55E-02
cg21429551 7 30635762 GARS - 3.40E-16 - 6.84E-04 - 8.70E-06 - 1.34E-02
cg19390658 7 30636176 GARS - 4.70E-09 - 2.58E-04 - 4.40E-06 - 3.30E-04
cg00008629 9 115093661 ROD1 - 6.50E-08 - 4.38E-03 - 8.00E-02 - 6.45E-02
cg11376147 11 57261198 SLC43A1 - 4.20E-21 - 6.66E-03 - 3.40E-12 - 1.34E-02
cg00574958 11 68607622 CPT1A - 1.20E-13 - 1.04E-02 - 3.00E-10 - 6.83E-04
cg00716257 14 75897417 JDP2 - 6.00E-08 - 4.39E-03 - 4.40E-07 - 4.28E-01
cg26916780 15 64889554 ZNF609 - 4.50E-06 - 8.87E-03 - 3.70E-09 - 5.77E-02
cg08857797 17 40927699 VPS25 + 3.60E-10 + 9.64E-06 + 2.30E-06 + 4.98E-05
cg22304262 19 47287778 SLC1A5 - 1.40E-17 - 1.97E-05 - 9.60E-11 - 1.05E-02
cg02711608 19 47287964 SLC1A5 - 2.00E-21 - 7.48E-06 - 4.30E-10 - 1.41E-03
cg21766592 19 47288066 SLC1A5 - 2.60E-08 - 5.65E-04 - 1.10E-01 - 1.88E-02
GenePositionChr. Probe ID
Table 3. Signals reported by CHARGE Consortium and replicated by the current study (FDR<0.05).
CHARGE META CHARGE META
SBP DBP
 
Table 4. Cross-validated CpG sites that show association with gene expression (±500kb) at FDR<0.05 in the Finnish Twin Cohort 
DNAm 
ProbeID 
DNAm 
annotation 
GX 
ProbID 
GX 
annotation 
DNAm-GX   GX-SBP   GX-DBP   DNAm-SBP   DNAm-DBP 
Dir. P FDR   Dir. P   Dir. P   Dir. P   Dir. P 
cg14476101 PHGDH 240086 PHGDH - 2.33E-11 1.19E-08 
 
+ 1.08E-01 
 
+ 5.62E-01 
 
- 1.33E-02 
 
- 2.88E-02 
cg16246545 PHGDH 240086 PHGDH - 2.94E-10 7.47E-08 
 
+ 1.08E-01 
 
+ 5.62E-01 
 
- 5.23E-02 
 
- 9.29E-02 
cg06500161 ABCG1 6060377 ABCG1 - 1.37E-04 1.39E-02   - 2.75E-03   - 4.49E-04   + 4.74E-02 
 
+ 2.51E-01 
cg12593793 Intergenic 6020424 LMNA - 3.60E-04 2.28E-02   + 2.57E-04   + 1.78E-05 
 
- 2.10E-01 
 
- 2.53E-01 
cg26916780 ZNF609 5960682 RBPMS2 - 8.61E-04 4.56E-02 
 
+ 1.88E-01 
 
+ 1.43E-01 
 
- 6.84E-01 
 
- 6.64E-01 
cg02711608 SLC1A5 7610433 SLC1A5 - 8.98E-04 4.56E-02   + 4.62E-01   + 2.88E-01   - 4.34E-02   - 1.07E-01 
GX: gene expression; Dir.: direction of the association 
DNAm-GX: the association between DNA methylation and gene expression; GX-SBP: the association between gene expression and SBP; GX-DBP: the association 
between gene expression and DBP.   
 
 
  
  
Probeid chr. Position Gene h2 95% CI
cg18933331 1 110186418 intergenic 0.72 0.62 - 0.81
cg16246545 1 120255941 PHGDH 0.77 0.69 - 0.84
cg14476101 1 120255992 PHGDH 0.74 0.63 - 0.82
cg19693031 1 145441552 TXNIP 0.56 0.53 - 0.60
cg19266329 1 145456128 intergenic 0.39 0.31 - 0.49
cg24955196 1 154982621 ZBTB7B 0.41 0.22 - 0.63
cg12593793 1 156074135 intergenic 0.65 0.37 - 0.86
cg01343041 2 24397787 C2orf84 0.65 0.62 - 0.68
cg18119407 2 201980504 CFLAR 0.36 0.33 - 0.39
cg06690548 4 139162808 SLC7A11 0.36 0.27 - 0.46
cg18120259 6 43894639 LOC100132354 0.63 0.56 - 0.69
cg21429551 7 30635762 GARS 0.68 0.65 - 0.71
cg19390658 7 30636176 GARS 0.35 0.32 - 0.38
cg19695041 8 38615330 TACC1 0.51 0.43 - 0.59
cg00008629 9 115093661 ROD1 0.78 0.65 - 0.87
cg13696706 9 124396830 DAB2IP 0.58 0.55 - 0.61
cg11376147 11 57261198 SLC43A1 0.41 0.25 - 0.59
cg11468085 11 67435577 ALDH3B2 0.54 0.51 - 0.57
cg00574958 11 68607622 CPT1A 0.44 0.30 - 0.58
cg00508575 12 90050967 ATP2B1 0.48 0.38 - 0.59
cg05248321 14 20898128 KLHL33 0.65 0.54 - 0.75
cg00716257 14 75897417 JDP2 0.31 0.11 - 0.62
cg02003183 14 103415882 CDC42BPB 0.62 0.59 - 0.65
cg26916780 15 64889554 ZNF609 0.40 0.34 - 0.46
cg12555233 15 91455366 MAN2A2 0.56 0.44 - 0.67
cg07558761 16 87866696 SLC7A5 0.53 0.38 - 0.68
cg07021906 16 87866833 SLC7A5 0.61 0.58 - 0.64
cg04583842 16 88103117 BANP 0.63 0.58 - 0.67
cg08857797 17 40927699 VPS25 0.48 0.21 - 0.75
cg22304262 19 47287778 SLC1A5 0.70 0.47 - 0.87
cg02711608 19 47287964 SLC1A5 0.69 0.61 - 0.75
cg21766592 19 47288066 SLC1A5 0.58 0.52 - 0.63
cg06500161 21 43656587 ABCG1 0.61 0.50 - 0.71
cg01820192 21 44869762 C21orf125 0.37 0.32 - 0.42
Table 5. Heritability of the 34 cross-validated CpG sites from the meta-analysis
Direction P rPh G contribution E contribution PG=0 PE=0
cg19693031 SBP TXNIP -- 0.0185 -0.047 0.023 (-0.040, 0.085) -0.070 (-0.132, -0.008) 0.477 0.026
cg13696706 SBP DAB2IP ++ 0.0120 0.059 0.036 (-0.026, 0.098) 0.023 (-0.039, 0.085) 0.254 0.464
cg11468085 SBP ALDH3B2 ++ 0.0148 0.026 -0.029 (-0.138, 0.079) 0.055 (-0.007, 0.116) 0.595 0.084
cg05248321 SBP KLHL33 ++ 0.0117 0.056 0.034 (-0.028, 0.096) 0.022 (-0.04, 0.084) 0.279 0.492
cg00716257 SBP JDP2 -- 0.0317 -0.050 0.013 (-0.050, 0.075) -0.063 (-0.124, -0.001) 0.692 0.048
cg04583842 SBP BANP ++ 0.0132 0.066 0.045 (-0.017, 0.107) 0.021 (-0.041, 0.083) 0.159 0.512
cg08857797 SBP VPS25 ++ 0.0029 0.070 0.018 (-0.044, 0.08) 0.052 (-0.01, 0.114) 0.568 0.101
cg22304262 SBP SLC1A5 -- 0.0252 -0.050 -0.030 (-0.118, 0.058) -0.020 (-0.082, 0.042) 0.509 0.535
cg06500161 SBP ABCG1 ++ 0.0417 0.031 0.003(-0.098, 0.105) 0.028 (-0.034, 0.090) 0.952 0.369
cg19693031 DBP TXNIP -- 0.0246 -0.062 -0.006 (-0.068, 0.056) -0.056 (-0.118, 0.006) 0.857 0.076
cg11468085 DBP ALDH3B2 ++ 0.0099 0.023 -0.013 (-0.126, 0.101) 0.036 (-0.037, 0.110) 0.828 0.333
cg08857797 DBP VPS25 ++ 0.0022 0.090 0.065 (-0.016, 0.146) 0.025 (-0.037, 0.087) 0.117 0.432
rph: phenotypic correlation; G contribution: genetic contribution; E contribution: unique environmental contribution. A detailed 
explanation is provided in Supplementary Data Figure S2.
Table 6. Meta analysis results of the bivariate SEM analysis for BP and its associated CpG sites in FTC and NTR
Probeid Trait Gene
Association Bivariate SEM analysis
NOVELTY AND SIGNIFICANCE 
What Is New? 
• Identified 13 novel CpG sites of which their methylation levels are associated with BP 
• Genetic factors contribute to the methylation variations of the BP associated CpG sites 
• The phenotypic correlations between CpG sites and SBP are primarily attributable to 
environmental factors that affect both traits, rather than genetic factors. 
What Is Relevant? 
• The identification of shared unique environmental factors rather than genetic factors between 
BP and DNA methylation indicates that the environment plays a significant role in creating an 
association between DNA methylation signatures and BP. 
  
Summary 
In this study of 4,820 individuals of European and African ancestry aged 14-69, genome-wide DNA 
methylation data from peripheral leukocytes were obtained using the Infinium HumanMethylation450k 
BeadChip and blood pressures were measured during clinical visit. Linear regression or mixed models 
were used to identify differentially methylated CpG sites associated with BP. Univariate and bivariate 
structural equation modelings were used to further investigate to what extent the genetic and 
environmental factors influence DNA methylation and blood pressure in the Finnish Twin Cohort and the 
Netherlands Twin Register. Our study identify 13 more CpG sites with their methylation levels associated 
with BP and replicated 21 previously identified signals. Univariate twin modeling showed that genetic 
factors contributed to the methylation variations of all the 34 CpG sites with heritability estimates 
ranging from 31-78%. Bivariate twin modeling showed that 100% of the correlations of systolic BP with 
cg19693031 (TXNIP) and cg00716257 (JDP2) were determined by environmental effects acting on both 
systolic BP and methylation levels, rather than genetic factors. 
Key words 
Blood pressure, DNA methylation, Epigenome-wide association study, Twin study, Hypertension 
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COHORT DESCRIPTION 
Finnish Twin Cohort (FTC): In 2011, a comprehensive questionnaire was sent to all the living twins of the 
Finnish Twin Cohort born between 1945 and 1957 (11738 twins). A total of  8501 twins returned the 
questionnaire with a response rate of 72% 1. Three questions in this questionnaire are related to 
hypertension: (1) When was your BP last measured? (2) Have you ever been told that you have elevated BP 
or hypertension? and (3) On how many days in the past year have you used antihypertensive medication? 
Based on the questionnaire, twins were defined as hypertensive if they had been diagnosed with 
hypertension or had taken antihypertensive medication for at least 2 months, while twins were defined as 
normotensive if they had not been diagnosed with hypertension and did not take antihypertensive 
medication. Based on the replies, 330 same-sex twin pairs free of self-reported previous diagnosis of 
myocardial infarction, congestive heart failure or stroke were defined as potentially discordant for 
hypertension. These twin pairs were phone interviewed and asked to participate in clinical assessments at 
the University of Helsinki during 2012-2015.  A total of 222 twin pairs and 3 singletons (n=447) participated 
in the clinical protocol. Informed consent was obtained from each subject, and the study was approved by 
the Ethics Committee of the University Central Hospital of Helsinki. 
        During the clinical testing, the twins had a comprehensive physical examination, and their health 
history was recorded, including questions again about previous diagnoses of hypertension and use of anti-
hypertensive medication. Resting BPs were measured four times during the visit, seated by a 
sphygmomanometer according to the JNC7 guidelines. The average of the last two readings of each 
measurement occasion was used to represent BP values. Information on medications was further 
complemented with data from community pharmacies. Based on the fact that only 50 twin pairs met the 
criteria for current discordance for hypertension (one twin on anti-hypertensive medication or with 
SBP≥140mmHg or DBP≥90mmHg and his/her co-twin not on anti-hypertensive medication, and with 
SBP<120mmHg and DBP<80mmHg), we included all the twins for the current analysis by using SBP and DBP 
as continuous variables. If antihypertensive medication was used, 15mmHg and 10mmHg were added to 
the measured SBP and DBP levels, respectively 2. Fasting peripheral blood samples were obtained from 402 
participants. Zygosity was determined by genotyping using Illumina HumanCoreExome  BeadChip.   
Georgia Stress and Heart study (GSH)3, 4: The GSH study is a longitudinal study, which was established in 
1989 with the goal of exploring the development of cardiovascular risk factors. It consisted of 396 EA and 
349 AA health youths aged from 7 to 16 years at baseline. All participants were recruited from the general 
population in the Augusta, Georgia area. The evaluation was conducted annually from 1989 to 2001 (visit 1-
10), and every 1.5 years from 2002 to 2007 (visit 11-14). Most recently two more visits were conducted 
from 2008 to 2012 (visit 15-16). Blood samples were collected from visit 9.  In the current study, all the 
participants in visit 15 with buffy coat available were selected for the current study (n=480).  
 
Epigenetic Basis of Obesity Induced Cardiovascular Disease and Type 2 Diabetes (EpiGO) study 5, 6.  The 
EpiGO study was established in 2011 with the goal of identifying methylation changes involved in the 
pathogenesis of obesity and its related co-morbidities.  The EpiGO study in total enrolled 351 obese (BMI 
percentile ≥95%) and 435 lean (BMI percentile ≤50%) youth aged 14 to 20 years with 70% of African-
Americans (AA), 30% of European-Americans (EA), 47% of males and 53% of females. All the subjects were 
recruited from the Augusta, Georgia area from 2011-2015. The youths were free of any acute or chronic 
illness, and did not take daily prescription medication to treat diseases. Illumina 450k data were obtained 
from 192 African-American participants (96 obese vs. 96 lean, 50% of females). After quality control, 
genome-wide DNA methylation data for 188 subjects (96 obese vs. 92 controls) were included in the 
current analysis.      
 
Lifestyle, Adiposity, and Cardiovascular Health in Youth (LACHY) study 5, 7: The LACHY study was 
established in 2000 and finished in 2004 with the goal of determining the relations of fatness and fitness to 
cardiovascular disease (CVD) risk factors in the juvenile years. It consisted of 756 youths aged from 14 to 18 
years recruited from general population, with roughly equal numbers of AA and EA of both genders. All 
participants were recruited from the Augusta, Georgia area. The youths were apparently healthy and did 
not take daily prescription medication to treat diseases. In this study, all AA participants with buffy coat 
available (n=286) were selected for the current study. After quality control, genome-wide DNA methylation 
data in leukocytes were available for 284 subjects.  
 
Jackson Heart Study (JHS): The JHS is a large, community-based, longitudinal study whose participants 
were recruited from the Jackson metropolitan area. The primary objective of the JHS is to investigate the 
causes of EH and cardiovascular disease to learn how best to prevent and treat these diseases in AAs 8. At 
baseline, a total of 5,302 AAs (21 to 94 years of age) were enrolled from 2000 to 2004. The participants 
have provided extensive medical and social history, and had an array of physical and biochemical 
measurements and diagnostic procedures.  In particular, BP and buffy coat DNA were collected. For the 
current study, we selected 48 EH cases (50% females and 48% on antihypertensive medication) and 48 age 
(±2 years), sex and BMI (within the same category) matched normotensive controls for the genome-wide 
DNA methylation analysis. The including criteria for EH cases were: (1) age<45; (2) having genome-wide 
SNP data; and (3) on anti-hypertensive medication, or having SBP≥130mmHg or DBP≥85mmHg. The 
including criteria for normotensive controls were: (1) age<45; (2) having genome-wide SNP data; and (3) 
having SBP<120mmHg and DBP<80mmHg. To be in consistent with other cohorts, the current analysis used 
SBP and DBP as continuous variables rather than the phenotype of hypertension. If antihypertensive 
medication was used, 15mmHg and 10mmHg were added to the measured SBP and DBP levels, respectively 
2. 
 
Prevention of REnal and Vascular ENd stage Disease (PREVEND): The PREVEND is an ongoing large 
population-based longitudinal cohort started in 1997 and conducted in Groningen, the Netherlands. The 
main objective is to study microalbuminuria as a risk factor for renal and cardiovascular disease 9, 10. During 
1997-1998, all inhabitants of the city of Groningen between the ages of 28 and 75 yr (85,421 subjects) were 
asked to send in a morning urine sample and to fill out a short questionnaire. A total of 40,856 subjects 
(47.8%) responded. Subjects with a urinary albumin concentration of ≥10 mg/L (n = 7,768) together with a 
randomly selected control group with a urinary albumin concentration of <10 mg/L (n = 3,395) were invited 
for further investigations in an outpatient clinic. In total, 8,592 subjects completed the baseline test. Of the 
8,592 subjects who completed the baseline test, 7928 Caucasians had buffy coat DNA available and BP 
measured. The current analysis included 2 genome-wide DNA methylation datasets from PREVEND. The 
first one included 98 EH cases (46.9% females and 35.7% on antihypertensive medication) and 98 age (±2 
years), sex and BMI (within the same category) matched normotensive controls. The including criteria for 
EH cases were: (1) age<50; (2) having genome-wide SNP data; and (3) on anti-hypertensive medication, or 
having SBP≥140mmHg or DBP≥90mmHg. The including criteria for normotensive controls were: (1) age<50; 
(2) having genome-wide SNP data; and (3) having SBP<120mmHg and DBP<80mmHg. The second dataset 
consisted of 111 randomly selected samples, of which 28.3% were female and 20.9% used anti-
hypertensive medication. 
 
Emory Twin Study (ETS): The ETS consists of 283 middle-aged male Caucasian MZ and DZ twin pairs from 
the Vietnam Era Twin Registry who were born between 1946 and 195611. All twins were examined in pairs 
at the Emory University General Clinical Research Center between 2002 and 2010. Genome wide DNA 
methylation data and measured BP were available in 218 twins aged 31-6612. In the current analysis we 
included all the twins with epigenetic and BP data. If antihypertensive medication was used, 15mmHg and 
10mmHg were added to the measured SBP and DBP levels, respectively 2. 
Lifelines sample: Lifelines is a prospective population-based cohort to study health and health-related 
behaviours of 167,729 individuals living in the North of The Netherlands 13. Details on clinical examination 
and biochemical measurements have been described elsewhere 13. In short, a standardized protocol was 
used to obtain blood pressure and anthropometric measurements such as height, weight and waist 
circumference. Blood was collected in the fasting state, between 08:00 and 10:00 in the morning. Five 
groups were selected for genome-wide DNA methylation measurement from the baseline of the Lifelines 
study (all unrelated and European ancestry samples, n=13,436) 14 using the following criteria (n=50 for each 
group): (1) type 2 diabetes patients without CVD complications; (2) type 2 diabetes patients with CVD 
complications; (3) non-diabetic controls, with no history of CVD risk factors, and age- and sex- matched to 
groups 1 and 2; (4) healthy, obesity subjects (BMI≥30kg/m2); and (5) healthy, normal-weight controls 
(BMI<25),  and age- and sex-matched to group 4.  The non-diabetic controls, healthy obesity subjects and 
normal-weight controls (n=150, i.e. group 3, 4, and 5) were included in the current analysis. 15 
Netherlands Twin Register (NTR) biobank project: For the NTR biobanking project,  participants and 
collection procedures of blood, urine and buccal sample were described in detail previously15. The study 
also included parents of twins, siblings of twins and spouses of twins. In total, 3,264 blood samples from 
3,221 NTR participants were assessed for genome-wide methylation, of which 3,089 samples from 3,057 
subjects passed quality control. Blood pressure was measured in a subset of NTR participants as part of 
several projects that used similar methodology 16. Here, we analyze SBP and DBP measured at rest. SBP and 
DBP were corrected for antihypertensive medication use by adding drug-class specific average treatment 
effects to the measured values 17, 18. Only samples with good-quality DNA methylation data, white blood 
cell counts and BP measured ±2years from the methylation measurement were retained for EWAS and 
bivariate twin modeling analysis, leaving 596 subjects (age at the methylation measurement: 29.4±10.5; 
66% females). This dataset included 499 MZ and 95 DZ twins as well as 2 spouses of twins. The univariate 
heritability analysis included 2802 twins (1736 MZ twins, and 1066 DZ twins) with good quality methylation 
data available. All subjects provided written informed consent. The study protocols were approved by the 
Central Ethics Committee on Research Involving Human Subjects of the VU University Medical Centre, 
Amsterdam, an Institutional Review Board certified by the US Office of Human Research Protections (IRB 
number IRB-2991 under Federal-wide Assurance-3703; IRB/institute codes, NTR 03-180). 
Dietary, Lifestyle, and Genetic determinants of Obesity and Metabolic syndrome study (DILGOM): The 
Finnish study samples included a total of 513 unrelated individuals aged 25–74 years from the Helsinki 
area, recruited during 2007 as part of the DILGOM study, an extension of the FINRISK 2007 study described 
earlier19. Study participants were asked to fast overnight (at least 10 hours) prior to giving a blood sample. 
Genome-wide DNA methylation data were obtained from 512 individuals (Male= 237, Female=275, mean 
age 51.9 ± 13.7). The blood pressure measurements of DILGOM were carried out approximately three 
months earlier at baseline investigation of the FINRISK 2007 survey. As described19, blood pressure 
measurements were performed by a trained nurse  from the right arm of the participant who had been 
resting in a sitting position for five minutes before the first measurement. A standard mercury 
sphygmomanometer with a cuff size 14 x 36 cm was used. The first phase of the Korotkoff sounds was 
taken as the systolic pressure and the fifth phase as the diastolic pressure. Three measurements were 
performed and the mean of the last two measures was used in the analyses.  
Estonian Genome Center of the University of Tartu (EGCUT) biobanking project: The EGCUT is the 
population-based database which comprises currently the health, genealogical and genome data of more 
than 51,530 individuals 18 years of age and up reflecting closely the age distribution in the adult Estonian 
population. Participants of EGCUT recruited by the general practitioners (GP) from GP offices, physicians 
from the hospitals or data collectors from EGCUT’s patient recruitment offices. Each participant filled out a 
Computer Assisted Personal interview during 1-2 hours at a doctor’s or data collector’s office, including 
personal data (place of birth, place(s) of living, nationality etc.), genealogical data (family history, three 
generations), educational and occupational history and lifestyle data (physical activity, dietary habits, 
smoking, alcohol consumption, quality of life). 20Anthropometric and physiological measurements were 
also taken. Resting BPs were measured three times during the visit, seated by a sphygmomanometer 
according to the JNC7 guidelines. The average of  three readings of each measurement occasion was used 
to represent BP values. If antihypertensive medication was used, 15mmHg and 10mmHg were added to the 
measured SBP and DBP levels, respectively. The current analysis included 2 genome-wide DNA methylation 
datasets from EGCUT. The first one included 91 asthma cases (mean age: 26.1±7.1 63.7% females) and 82 
age- and gender-matched controls (mean age: 24.6±6.0, 64.6% females). Both cases and controls were 
required to have BMI<30kg/m2 and to be non-smokers. The second one included 50 younger (age 22–34, 
52% females) and 50 older (age 73–84, 52% females) individuals.   
The Bogalusa Heart Study (BHS): The BHS, a long-term epidemiology study of the natural history of 
cardiovascular disease from childhood to adulthood, was founded by Dr. Gerald Berenson in 1973 21. The 
current study cohort consisted of 968 adult participants (680 whites and 288 blacks, 421 males, mean 
age=43.2±4.5 years) who had been recruited in the BHS from 2006 to 2010. Anthropometry and BP were 
measured in the morning. Participants’ BP levels were obtained on right arms in a relaxed sitting position 
by 2 trained observers (3 times each). Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were 
recorded using a mercury sphygmomanometer. The mean values of the 6 readings were used for analysis. 
Whole blood samples were collected between 8:00 AM and 10:00 AM after overnight fasting for DNA 
methylation profiles assays. All participants in the BHS gave informed written consent. Study protocols 
were approved by the Institutional Review Board of Tulane University. 
 
The Helsinki Birth Cohort (HBC): The HBCS comprises 13345 individuals (6370 women and 6975 men), born 
as singletons between 1934 and 1944 in one of the two main maternity hospitals in Helsinki and who were 
living in Finland in 1971 when a unique personal identification number was allocated to each member of 
the Finnish population. The HBCS, which has been described in detail elsewhere 22, has been approved by 
the Ethics Committee of the National Public Health Institute. Register data were linked with permission 
from the Finnish Ministry of Social Affairs and Health and the Finnish National Archives. In 2001–2004 at an 
average age of 61.5 years (s.d. = 2.9 and range = 56.7 –69.8 years), a randomly selected subsample of the 
cohort comprising 2003 individuals (1075 women and 928 men) was invited to a clinical examination 
including collection of a blood sample for (epi)genetic and biochemical studies. Genome-wide DNA 
methylation data were obtained from 83 evacuated men (mean age: 64±2.9 years) and 83 non-evacuated 
controls (mean age: 62.4±2.6 years) matched for sex, birth year and father’s occupational status in 
childhood 23. Blood pressure data were available for 164 participants. Blood pressure was measured from 
the right arm while the subject was in the sitting position, and it was recorded as the mean of 2 successive 
readings from a mercury sphygmomanometer. All measurements were performed by a team of 3 trained 
research nurses.  
The Young Finns study (YFS): 24YFS comprises a series of six cohorts, representing general population, born 
in 1962, 1965, 1968, 1971, 1974 and 1977 from five cities with university hospitals in Finland (Helsinki, 
Kuopio, Oulu, Tampere and Turku) [18]. A subsample of 188  (Male= 115, Female=73, mean age 44.0 ± 3.3) 
individuals were randomly assigned from a follow-up in 2011. The sample collection in 2011 is described in 
more detail elsewhere [34]. The categories of age in the methylation analysis were 40, 43, 46 and 49 years 
old, with group sizes of 50, 44, 55 and 35, in which 58 %, 68.2, 56.4 and 60 % were women, respectively. All 
of the participants were of western European descent. The study followed the guidelines of the Declaration 
of Helsinki and was approved by the Ethical Review Committee of Turku University Hospital. All participants 
provided informed consent. Blood pressure from the right brachial artery was measured in the sitting 
position after a 5-minute rest with a random-zero sphygmomanometer (Hawksley & Sons Ltd, Lancin, 
United Kingdom) as described previously 25. The average of three measurements was used in the analysis. 
Hypertension was defined as systolic blood pressure ≥140 mm Hg, diastolic blood pressure ≥90 mm Hg, 
self-reported use of antihypertensive medication, or a self-reported hypertension diagnosis. 
The Lifelines DEEP cohort: This cohort was not included in the current meta-analysis. It was used as an 
independent cohort to evaluate the contribution of the CpG sites to BP variation. A total of 601 adults (age: 
45.6±13.1 years; 58.2% females, 9.48% taking antihypertensive medications) from the Lifelines DEEP cohort 
were included in this study based on available epigenome-wide methylation data and BP. If 
antihypertensive medication was used, 15mmHg and 10mmHg were added to the measured SBP and DBP 
levels, respectively. Initially, 1539 participants were enrolled in the Lifelines DEEP, which is a subpopulation 
of the Lifelines cohort in the north of The Netherlands 14, 26. Except for the regular Lifelines procedures, 
additional deep molecular measurements were performed in Lifelines DEEP participants. All participants 
provided written informed consent. The Lifelines DEEP study was approved by the Medical Ethical 
Committee of the University Medical Center Groningen (UMCG), Groningen, The Netherlands.  
GENOME-WIDE DNA METHYLATION PROFILING AND PROPROCESSING QUALITY CONTROL 
The FTC, JHS, PREVEND, GSH, EpiGO, LACHY, YFS, DILGOM and ETS: The Minfi package 27 and CPACOR 
(incorporating Control Probe Adjustment and reduction of global CORrelation) package 28 were used for 
initial quantification, data preprocessing and quality control (QC). The key QC steps included: (1) Detectable 
probes were defined as the probes with detection P-value < 1x10-16 in more than 95% samples; (2) 
Detectable samples were defined as the samples with more than 95% CpG sites having a detection P-value 
<1x10-16 and correct classification of gender based on the genome-wide DNA methylation data; (3) Probes 
on the X and Y chromosomes and the 65 SNP markers were excluded; (4) Illumina background correction 
and quantile normalization were applied to all intensity values and beta value was further calculated and 
used as the index of CpG methylation levels; (5) A principal component analysis (PCA) of the control probe 
intensities (excluding negative control probes) was performed and the resulting PCs up to 30 (different 
numbers were used by different cohorts) were stored; (6) White blood cell sub-populations were estimated 
using the approach described by Houseman et al. 29; (7) A linear regression model was conducted for each 
CpG site with DNA methylation level as the dependent variable and the PCs from the control probe 
intensities as well as the estimated cell compositions as the independent variables. The residuals were 
calculated and used as indices of DNA methylation levels in further analysis.  The above steps were 
conducted for each cohort separately.  
BHS: The methylation data were normalized using the R package watermelon30. Given the importance of 
cellular heterogeneity in DNAm, we estimated the relative proportions of six pure cell types (CD4+ and 
CD8+ T-cells, natural killer cells, monocytes, granulocytes, and b-cells) in each sample using the R package 
Minfi package 27. For correction of systematic technical biases in the 450K assay, the β scores were 
normalized using the dasen function, in which type I and type II intensities and methylated and 
unmethylated intensities are quantile-normalized separately after backgrounds equalization of type I and 
type II probes. Based on bead count and detection p-values, the following thresholds were set for removal: 
1) samples having 1% of CpG sites with a detection p-value>0.05; 2) probes having 5% of samples with a 
detection p-value>0.05; 3) probes with bead count less than 3 in 5% of samples. 
NTR: The methylation data were examined with the R-package MethylAid 31. Only samples that passed all 
five quality criteria (using the default MethylAid thresholds) were kept for further analyses. Several probe-
level QC steps were performed to filter out probes with low performance. For all samples, ambiguously 
mapped probes were excluded, based on the definition of an overlap of at least 47 bases per probe from 
Chen et al. 32, and all probes containing a SNP, identified in the Dutch population33, within the CpG site (at 
the C or G position) were excluded, irrespective of minor allele frequency. For each sample individually, 
probes with an intensity value of zero (not present on the array of a particular sample), probes with a 
detection P value>0.01, and probes with a bead count <3 were excluded. After these steps, probes with a 
success rate <0.95 across samples were removed from all samples. The total number of CpGs after these 
filtering steps was 421,119. Only autosomal sites were kept in the current analyses (N=411,169). 
EGCUT: Data pre-processing and quality control analyses were performed in R with the Bioconductor 
package minfi27, using the original IDAT files extracted from the HiScanSQ scanner. ‘Raw’ pre-processing 
was used to convert the intensities from the red and the green channels into methylated and unmethylated 
signals. Beta values were computed using Illumina’s formula [beta = M/(M + U + 100)]. The difference in the 
distribution of beta values for type I and type II probes was corrected using “SWAN”, a normalization 
method to address systematic changes between type I and type II probes. Detection p-values were 
obtained for every CpG probe in each sample. Qualified CpG sites were defined as probes with detection P-
value<0.01 in ≥95% of the samples. Qualified samples were defined as samples having ≥90% of CpG sites 
with detection P-value<0.01. Only autosomal sites were kept in the final analyses.  
Lifelines: DNA methylation data were generated by the Genome Analysis Facility of UMCG, the Netherlands 
(www.rug.nl/research/genetics/genomeanalysisfacility/). Quality control (QC) and normalization steps are 
described in detail elsewhere 34 and in ESM Methods. In short, the QC pipeline by Touleimat and Tost was 
used with background correction and probe type normalization 35. Then, normalized beta-values were log-
transformed into M-values for downstream analysis, since they have been shown to perform better in 
studies with smaller sample sizes 36. 
HBC: Quality control pipeline was set up using the R-package minfi, including intensity readouts, 
normalization, cell type composition estimation, β- and M-value calculation. We excluded samples with 
low intensity (badSampleCutoff<10.6) or deviant beta distribution based on visual inspection 
(n=5). We did not detect any gender discrepancy. Data were normalized with functional normalization 
(FunNorm). Of the probes, we excluded those with detection p-value >0.01 in >50% of samples (ref. 
Minfi), non-autosomal and non-specific binding probes as well as probes with SNPs in the interval 
for which the Illumina probe is designed to hybridize and if they were located close (10bp from 
query site) to a SNP which had a minor allele frequency of ≥0.05. Probes located in the X and Y 
chromosome were also excluded.  This yielded a total number of probes of 424,844. Batch effects were 
identified by inspecting the association of principal components of the methylation levels with possible 
technical batches using linear regressions and visual inspection of PCA plots using the Bioconductor R 
package shinyMethyl (version 0.99.3). Identified batch effects (i.e. array column) were removed using the 
Empirical Bayes' (EB) method ComBat 37. Batch corrected beta values after ComBat were used for all further 
statistical analyses and white blood cell sub-populations were estimated using the Houseman et al 29. 
The Lifelines Deep Cohort: For genome-wide DNA methylation data, 500 ng of genomic DNA was bisulfite-
converted using the EZ DNA Methylation kit (Zymo Research Corp., USA) and hybridized on Illumina Human 
Methylation 450K BeadChip arrays (Illumina, Inc.) according to the manufacturer’s protocols. The original 
IDAT files were generated by the Illumina iScan BeadChip scanner and performed by the Human 
Genotyping facility (HugeF) of ErasmusMC, The Netherlands (http://www.glimDNA.org/). Quality control 
and normalization details are described elsewhere (unpublished manuscript). Briefly, the R-package “minfi” 
was used to check on the quality of probes and samples. By following the Touleimat and Tost’s pipeline 35, 
we performed background correction and probe type normalization using preprocessQuantile 
implemented in the minfi package 27. Methylation levels at each CpG site were expressed as the ratios of 
the methylated intensity over the total intensity (β-values). Normalized M-values were used for all 
subsequent statistical analyses, while β-values were used for biological interpretation in tables and figures.  
FIGURE LEGEND 
Figure S1. Flow diagram of the study design. 
 
Figure S2. Path diagram for univariate structural equation model 
The observed phenotypes (P) for co-twins are shown in squares, and latent factors are shown in circles. 
Correlation between genetic factors (A) is 1 in monozygotic (MZ) twin pairs and 0.5 in dizygotic (DZ) twin 
pairs. Correlation between common (or shared) environmental factors (C) is 1 for MZ/DZ twin pairs. Unique 
environmental factors (E) are always uncorrelated. 
 
Figure S3. Path diagram for bivariate structural equation model (Cholesky model) 
The observed two phenotypes (P1, P2) for co-twins are shown in squares, and latent factors are shown in 
circles. Similar to the univariate model, correlation between genetic factors of the same phenotype (A1, A2) 
is 1 in monozygotic (MZ) twin pairs and 0.5 in dizygotic (DZ) twin pairs, while correlation between common 
(or shared) environmental factors (C) is 1 for both MZ/DZ twin pairs. Unique environmental factors (E) are 
always uncorrelated between two twins. The paths of genetic factors on each phenotype are a11 and a22 
respectively, and the path of genetic factors between two phenotypes is a21. Similarly, The paths of 
common and unique environmental factors on each phenotype are c11 and c22, and e11 and e22, respectively, 
and the path of common and unique environmental factors between two phenotypes are c21 and e21. As 
the correlation is the standardized covariance, we can calculate the genetic correlation (rg) based on the 
variance/covariance matrix estimated from the bivariate twin modeling, i.e. rg= 
(𝑎𝑎11×𝑎𝑎21)
�𝑎𝑎112 ×(𝑎𝑎212 +𝑎𝑎222 )
, and the 
common and unique environmental correlations (rc and re) as well, i.e. rc= 
(𝑐𝑐11×𝑐𝑐21)
�𝑐𝑐112 ×(𝑐𝑐212 +𝑐𝑐222 )
 and re= 
(𝑒𝑒11×𝑒𝑒21)
�𝑒𝑒112 ×(𝑒𝑒212 +𝑒𝑒222 )
. The genetic contribution to the observed phenotypic correlation (rph) is a function of both 
heritabilities of the two phenotypes and the rg between them, i.e. �ℎ12 × 𝑟𝑟𝑔𝑔 × �ℎ22. Similarly, the 
environmental contributions to the observed correlation are equal to �𝑐𝑐12 × 𝑟𝑟𝑐𝑐 × �𝑐𝑐22 and �𝑒𝑒12 × 𝑟𝑟𝑒𝑒 × �𝑒𝑒22. 
Dividing these terms by rph yields the proportion of rph due to genetic, common and unique environmental 
factors, repectively, because rph = �ℎ12 × 𝑟𝑟𝑔𝑔 × �ℎ22 + �𝑐𝑐12 × 𝑟𝑟𝑐𝑐 × �𝑐𝑐22 + �𝑒𝑒12 × 𝑟𝑟𝑒𝑒 × �𝑒𝑒22. 
Figure S4. Manhattan plot of the genome-wide DNA methylation analysis. The blue line indicates the 
threshold of P<1E-05. Figure S4a: SBP; Figure S4b: DBP. 
Figure S5. QQ plot of the genome-wide DNA methylation analysis. Figure S5a: SBP; Figure S5b: DBP. 
Figure S6. Scatter plot of the assocations between DNA methylation and gene expression. X axis is DNA 
methylation level, which are the residuals of beta values after  regressing out the effect of cell composition 
and 5 PCs from the control probes. Y axis is gene expression level, which are the residuals of the gene 
expression levels after regressing out the batch effect.   
Table S1. CpG sites associated with SBP or DBP at P<1×10-5 from our meta-analysis. 
Probe ID Chr. Gene 
SBP     DBP    
Direction P value Het P value   Direction P value Het P value 
cg06500161 21 ABCG1 + 5.69E-06 5.79E-03 
 
+ 5.06E-05 3.45E-02 
cg11468085 11 ALDH3B2 + 4.16E-06 2.32E-01 
 
+ 1.38E-04 2.22E-01 
cg00508575 12 ATP2B1 + 6.47E-06 4.50E-02 
 
+ 9.20E-04 2.62E-01 
cg04583842 16 BANP + 5.54E-09 2.91E-01 
 
+ 2.99E-06 2.33E-01 
cg05166473 16 BANP + 1.26E-06 4.31E-01 
 
+ 8.71E-04 4.45E-01 
cg01820192 21 C21orf125 + 6.44E-06 9.82E-01 
 
+ 3.96E-02 5.67E-01 
cg14562076 21 C21orf125 + 2.93E-06 4.35E-01 
 
+ 3.38E-03 2.41E-01 
cg01343041 2 C2orf84 + 4.21E-07 5.77E-01 
 
+ 1.01E-04 1.08E-01 
cg18587476 2 C2orf84 + 3.98E-06 6.66E-01 
 
+ 3.59E-03 2.51E-01 
cg19849557 6 C6orf136 + 2.64E-06 7.81E-01 
 
+ 4.07E-02 5.50E-01 
cg02003183 14 CDC42BPB + 3.66E-07 2.85E-01 
 
+ 1.54E-03 9.01E-02 
cg10258505 14 CDC42BPB + 3.95E-06 8.64E-01 
 
+ 2.43E-04 2.80E-01 
cg23570433 11 CTR9 + 2.52E-03 6.34E-01 
 
+ 3.07E-06 3.14E-01 
cg13696706 9 DAB2IP + 9.83E-08 5.55E-01 
 
+ 1.16E-03 8.16E-01 
cg10785537 2 DCTN1 + 6.50E-06 3.81E-01 
 
+ 2.43E-02 3.90E-01 
cg24461627 10 DIP2C + 2.35E-05 9.57E-01 
 
+ 6.49E-06 3.78E-01 
cg19637821 12 FBRSL1 + 4.98E-07 6.38E-01 
 
+ 2.15E-02 2.08E-01 
cg22590032 5 FLT4 + 3.94E-06 2.03E-01 
 
+ 3.06E-03 6.15E-01 
cg10342963 15 IGF1R + 2.91E-07 4.26E-01 
 
+ 6.48E-05 6.32E-01 
cg05248321 14 KLHL33 + 7.01E-07 8.70E-01 
 
+ 1.88E-03 9.76E-01 
cg08059112 19 LINGO3 + 2.42E-06 6.52E-01 
 
+ 1.85E-03 6.28E-01 
cg12555233 15 MAN2A2 + 2.74E-06 4.87E-02 
 
+ 3.50E-03 2.90E-01 
cg03835709 12 NAV3 + 8.75E-06 1.21E-01 
 
+ 8.24E-03 6.20E-01 
cg13673536 9 PIP5K1B + 1.73E-04 3.32E-01 
 
+ 4.24E-07 8.25E-01 
cg20738719 3 SEMA5B + 2.23E-07 3.36E-01 
 
+ 2.23E-04 7.02E-01 
cg26401492 3 SFMBT1 + 1.08E-02 1.15E-02 
 
+ 5.92E-06 5.16E-01 
cg02711608 19 SLC1A5 - 7.48E-06 2.50E-03 
 
- 1.41E-03 3.36E-02 
cg07021906 16 SLC7A5 + 1.38E-06 6.98E-01 
 
+ 3.37E-03 4.38E-01 
cg07558761 16 SLC7A5 + 8.83E-07 1.90E-01 
 
+ 1.71E-03 8.45E-02 
cg04690793 6 SNRPC + 3.98E-06 9.09E-01 
 
+ 1.57E-03 4.90E-01 
cg02980023 3 STAB1 + 3.78E-07 2.84E-01 
 
+ 5.86E-06 5.31E-01 
cg19695041 8 TACC1 - 6.26E-06 8.09E-01 
 
- 3.36E-02 5.34E-01 
cg19693031 1 TXNIP - 2.18E-07 1.23E-03 
 
- 4.65E-05 7.63E-02 
cg08857797 17 VPS25 + 9.64E-06 6.44E-01 
 
+ 4.98E-05 7.75E-01 
cg00916854 12 VPS37B + 7.99E-06 8.48E-02 
 
+ 2.06E-03 1.20E-01 
cg09012734 21 WDR4 + 3.38E-02 2.52E-01 
 
+ 8.42E-06 2.21E-01 
cg00989229 16 Intergenic + 1.37E-02 6.58E-01 
 
+ 8.30E-06 3.47E-01 
cg03411579 12 Intergenic + 9.35E-07 2.54E-01 
 
+ 2.68E-04 2.19E-01 
cg08232160 16 Intergenic + 9.11E-06 1.86E-01   + 5.15E-03 5.82E-03 
  
  
Probe ID Chr. Gene Direction P value Direction P value Direction P value Direction P value
cg18933331 1 intergenic - 2.16E-02 - 1.89E-02 + 6.17E-01 + 9.88E-01
cg16246545 1 PHGDH - 5.20E-04 - 1.14E-02 - 5.78E-01 - 7.89E-01
cg14476101 1 PHGDH - 1.20E-04 - 7.11E-03 - 7.23E-01 - 6.20E-01
cg19693031 1 TXNIP - 1.23E-02 - 4.82E-04 - 1.20E-03 + 7.17E-01
cg19266329 1 intergenic - 1.93E-01 - 9.85E-01 - 4.01E-01 + 7.11E-02
cg24955196 1 ZBTB7B + 1.54E-02 + 4.18E-03 + 5.80E-03 + 3.00E-02
cg12593793 1 intergenic - 1.66E-01 - 3.26E-01 - 5.52E-03 - 5.47E-01
cg01343041 2 C2orf84 + 2.18E-02 + 9.93E-02 + 9.19E-03 + 1.65E-01
cg18119407 2 CFLAR - 4.32E-02 - 1.38E-03 - 3.72E-01 + 3.60E-01
cg06690548 4 SLC7A11 - 2.21E-03 - 1.61E-04 - 5.32E-01 - 8.79E-02
cg18120259 6 LOC100132354 - 7.20E-02 - 6.90E-01 - 7.03E-01 - 5.75E-01
cg21429551 7 GARS - 1.20E-02 - 3.43E-02 - 9.55E-01 + 8.10E-01
cg19390658 7 GARS - 8.64E-04 - 2.48E-02 - 9.86E-01 + 7.45E-01
cg19695041 8 TACC1 - 2.97E-04 - 5.92E-01 - 5.55E-02 - 6.36E-03
cg00008629 9 ROD1 - 2.27E-01 - 9.84E-01 - 1.85E-02 - 1.80E-01
cg13696706 9 DAB2IP + 9.16E-06 + 1.39E-02 + 3.52E-04 + 8.21E-02
cg11376147 11 SLC43A1 - 1.88E-02 - 1.83E-02 - 8.51E-01 + 9.60E-01
cg11468085 11 ALDH3B2 + 9.01E-05 + 2.04E-03 + 2.69E-01 + 4.39E-01
cg00574958 11 CPT1A - 4.65E-01 - 9.28E-02 - 9.61E-01 - 4.11E-01
cg00508575 12 ATP2B1 + 5.45E-03 + 3.01E-02 + 8.62E-04 + 1.43E-01
cg05248321 14 KLHL33 + 2.87E-04 + 6.44E-03 + 4.41E-02 + 3.78E-01
cg00716257 14 JDP2 - 6.42E-02 - 6.81E-01 - 7.37E-01 - 2.68E-01
cg02003183 14 CDC42BPB + 1.44E-05 + 5.92E-02 + 4.18E-01 - 2.39E-01
cg26916780 15 ZNF609 - 1.56E-01 - 2.27E-01 - 5.27E-01 + 9.09E-01
cg12555233 15 MAN2A2 + 2.35E-05 + 1.63E-03 + 8.16E-02 + 9.62E-01
cg07558761 16 SLC7A5 + 3.96E-05 + 3.37E-02 + 1.21E-01 + 6.48E-01
cg07021906 16 SLC7A5 + 8.72E-05 + 1.10E-02 + 3.17E-02 + 2.09E-01
cg04583842 16 BANP + 5.29E-07 + 3.97E-05 + 2.82E-02 + 5.99E-02
cg08857797 17 VPS25 + 4.46E-04 + 8.65E-05 + 8.39E-01 + 7.14E-01
cg22304262 19 SLC1A5 - 4.64E-03 - 1.79E-01 - 5.54E-01 - 9.50E-01
cg02711608 19 SLC1A5 - 2.52E-02 - 6.34E-01 - 6.54E-01 + 5.66E-01
cg21766592 19 SLC1A5 - 6.69E-03 - 4.70E-01 - 8.66E-02 + 9.17E-01
cg06500161 21 ABCG1 + 3.43E-02 + 2.98E-02 + 7.19E-01 - 8.97E-01
cg01820192 21 C21orf125 + 6.41E-04 + 7.01E-02 + 1.90E-01 + 5.00E-01
Table S2. Stratified analysis of the 34 CpG sites in participants with or without antihypertensive medication
SBP DBP
Without medication (n=3855)
SBP DBP
With medication (n=790)
 
  
ProbeID chr. Position Gene Direction P value
cg18933331 1 110186418 intergenic + 0.40982
cg16246545 1 120255941 PHGDH - 0.59214
cg14476101 1 120255992 PHGDH - 0.24269
cg19693031 1 145441552 TXNIP + 0.42444
cg19266329 1 145456128 intergenic + 0.30504
cg24955196 1 154982621 ZBTB7B - 0.367741
cg12593793 1 156074135 intergenic - 0.00561
cg01343041 2 24397787 C2orf84 + 0.199573
cg18119407 2 201980504 CFLAR + 0.07703
cg06690548 4 139162808 SLC7A11 - 0.18537
cg18120259 6 43894639 LOC100132354 - 0.0603
cg21429551 7 30635762 GARS + 0.96625
cg19390658 7 30636176 GARS + 0.24793
cg19695041 8 38615330 TACC1 - 0.06736
cg00008629 9 115093661 ROD1 + 0.09652
cg13696706 9 124396830 DAB2IP + 0.3064
cg11376147 11 57261198 SLC43A1 - 0.001
cg11468085 11 67435577 ALDH3B2 + 0.26652
cg00574958 11 68607622 CPT1A - 0.4117
cg00508575 12 90050967 ATP2B1 + 0.38144
cg05248321 14 20898128 KLHL33 - 0.84643
cg00716257 14 75897417 JDP2 + 0.52039
cg02003183 14 103415882 CDC42BPB + 0.82545
cg26916780 15 64889554 ZNF609 - 0.32459
cg12555233 15 91455366 MAN2A2 + 0.85009
cg07558761 16 87866696 SLC7A5 + 0.69759
cg07021906 16 87866833 SLC7A5 + 0.61261
cg04583842 16 88103117 BANP + 0.8756
cg08857797 17 40927699 VPS25 - 0.08236
cg22304262 19 47287778 SLC1A5 + 0.14571
cg21766592 19 47288066 SLC1A5 - 0.04095
cg06500161 21 43656587 ABCG1 + 0.00749
cg01820192 21 44869762 C21orf125 - 0.7618
Table S3. Associations of the 33 CpG sites with EH in Lifelines DEEP cohort
Table S4. GSEA results of our meta-analysis (FDR<0.05) 
Trait Biological Process Pathways FDR  
SBP CELL SUBSTRATE ADHERENS JUNCTION ASSEMBLY 0.029 
 
CELL SUBSTRATE JUNCTION ASSEMBLY 0.032 
 
CALCIUM ION IMPORT INTO CYTOSOL 0.039 
 
ADHERENS JUNCTION ASSEMBLY 0.050 
  NEUTRAL AMINO ACID TRANSPORT 0.060 
DBP REGULATION OF GRANULOCYTE DIFFERENTIATION 0.003 
 
REGULATION OF DENDRITE EXTENSION 0.007 
 
MEMBRANE BIOGENESIS 0.028 
 
PROTEIN AUTOPHOSPHORYLATION 0.030 
 
MEMBRANE ASSEMBLY 0.034 
 
REGULATION OF PROTEIN AUTOPHOSPHORYLATION 0.042 
  NEUTRAL AMINO ACID TRANSPORT 0.074 
The pathway previously identified by the CHARGE consortium was highlighted in grey. 
  
 
  
h2 95%CI h2 95%CI
cg18933331 1 110186418 intergenic 0.77 0.69 - 0.83 0.68 0.64 - 0.71
cg16246545 1 120255941 PHGDH 0.73 0.63 - 0.80 0.81 0.79 - 0.83
cg14476101 1 120255992 PHGDH 0.69 0.57 - 0.77 0.78 0.76 - 0.81
cg19693031 1 145441552 TXNIP 0.58 0.46 - 0.68 0.55 0.50 - 0.59
cg19266329 1 145456128 intergenic 0.44 0.28 - 0.57 0.35 0.29 - 0.40
cg24955196 1 154982621 ZBTB7B 0.53 0.40 - 0.63 0.31 0.24 - 0.37
cg12593793 1 156074135 intergenic 0.77 0.69 - 0.84 0.51 0.46 - 0.55
cg01343041 2 24397787 C2orf84 0.64 0.52 - 0.73 0.65 0.61 - 0.69
cg18119407 2 201980504 CFLAR 0.37 0.22 - 0.51 0.36 0.30 - 0.41
cg06690548 4 139162808 SLC7A11 0.31 0.08 - 0.51 0.40 0.35 - 0.46
cg18120259 6 43894639 LOC100132354 0.66 0.54 - 0.75 0.60 0.56 - 0.64
cg21429551 7 30635762 GARS 0.67 0.55 - 0.75 0.70 0.66 - 0.73
cg19390658 7 30636176 GARS 0.37 0.21 - 0.51 0.34 0.28 - 0.40
cg19695041 8 38615330 TACC1 0.55 0.41 - 0.66 0.47 0.42 - 0.52
cg00008629 9 115093661 ROD1 0.83 0.77 - 0.87 0.72 0.69 - 0.75
cg13696706 9 124396830 DAB2IP 0.57 0.44 - 0.67 0.59 0.55 - 0.63
cg11376147 11 57261198 SLC43A1 0.50 0.35 - 0.63 0.33 0.27 - 0.39
cg11468085 11 67435577 ALDH3B2 0.54 0.41 - 0.65 0.54 0.50 - 0.59
cg00574958 11 68607622 CPT1A 0.51 0.38 - 0.62 0.37 0.31 - 0.42
cg00508575 12 90050967 ATP2B1 0.54 0.41 - 0.65 0.43 0.37 - 0.48
cg05248321 14 20898128 KLHL33 0.71 0.60 - 0.79 0.60 0.56 - 0.64
cg00716257 14 75897417 JDP2 0.46 0.30 - 0.60 0.19 0.12 - 0.25
cg02003183 14 103415882 CDC42BPB 0.62 0.49 - 0.72 0.62 0.58 - 0.66
cg26916780 15 64889554 ZNF609 0.43 0.38 - 0.57 0.37 0.31 - 0.42
cg12555233 15 91455366 MAN2A2 0.62 0.51 - 0.71 0.50 0.45 - 0.55
cg07558761 16 87866696 SLC7A5 0.61 0.48 - 0.71 0.45 0.40 - 0.50
cg07021906 16 87866833 SLC7A5 0.61 0.49 - 0.71 0.61 0.57 - 0.65
cg04583842 16 88103117 BANP 0.65 0.53 - 0.74 0.61 0.56 - 0.64
cg08857797 17 40927699 VPS25 0.63 0.51 - 0.72 0.33 0.27 - 0.38
cg22304262 19 47287778 SLC1A5 0.80 0.73 - 0.85 0.59 0.54 - 0.63
cg02711608 19 47287964 SLC1A5 0.72 0.62 - 0.80 0.65 0.61 - 0.68
cg21766592 19 47288066 SLC1A5 0.55 0.41 - 0.65 0.60 0.56 - 0.64
cg06500161 21 43656587 ABCG1 0.66 0.55 - 0.75 0.56 0.51 - 0.60
cg01820192 21 44869762 C21orf125 0.34 0.18 - 0.48 0.39 0.33 - 0.44
Table S5. Heritability of the 34 cross-validated CpG sites in the FTC and NTR cohorts
FTC NTR
Probeid Chr. Position Gene
 
 
 
 
 
 
 
 
 a21 e21  a21 e21
cg19693031 TXNIP SBP -0.009(-0.244, 0.253) -0.203(-0.36, -0.044) 0.943 0.019 0.068(-0.088, 0.224) -0.13(-0.252, -0.003) 0.396 0.045
cg13696706 DAB2IP SBP 0.102(-0.149, 0.352) 0.041(-0.132, 0.213) 0.421 0.644 0.042(-0.109, 0.191) 0.068(-0.059, 0.193) 0.587 0.294
cg11468085 ALDH3B2 SBP -0.182(-0.453, 0.067) 0.168(-0.002, 0.327) 0.155 0.053 0.034(-0.111, 0.178) 0.098(-0.031, 0.223) 0.645 0.136
cg05248321 KLHL33 SBP 0.13(-0.101, 0.359) 0.029(-0.152, 0.207) 0.266 0.759 0.013(-0.134, 0.157) 0.082(-0.046, 0.206) 0.866 0.208
cg00716257 JDP2 SBP 0.023(-0.259, 0.348) -0.119(-0.288, 0.059) 0.878 0.188 0.042(-0.177, 0.225) -0.117(-0.238, 0.008) 0.754 0.066
cg04583842 BANP SBP 0.052(-0.189, 0.282) 0.105(-0.073, 0.275) 0.666 0.247 0.086(-0.063, 0.233) 0.01(-0.12, 0.139) 0.255 0.886
cg08857797 VPS25 SBP 0.088(-0.147, 0.314) 0.072(-0.102, 0.24) 0.455 0.413 -0.002(-0.186, 0.176) 0.146(0.02, 0.267) 0.983 0.024
cg22304262 SLC1A5 SBP -0.133(-0.327, 0.074) -0.124(-0.294, 0.054) 0.202 0.171 0.017(-0.128, 0.161) -0.014(-0.144, 0.117) 0.822 0.837
cg06500161 ABCG1 SBP 0.109(-0.12, 0.328) 0.088(-0.087, 0.257) 0.345 0.325 -0.07(-0.218, 0.079) 0.061(-0.067, 0.187) 0.355 0.350
cg19693031 TXNIP DBP 0.048(-0.207, 0.329) -0.148(-0.308, 0.021) 0.722 0.086 -0.041(-0.197, 0.118) -0.106(-0.231, 0.022) 0.612 0.103
cg11468085 ALDH3B2 DBP -0.167(-0.469, 0.102) 0.147(-0.021, 0.305) 0.229 0.085 0.065(-0.083, 0.211) 0.01(-0.118, 0.139) 0.392 0.875
cg08857797 VPS25 DBP 0.227(-0.018, 0.471) -0.021(-0.191, 0.15) 0.069 0.807 0.055(-0.131, 0.235) 0.106(-0.021, 0.229) 0.557 0.101
rg: genetic correlation; re: unique environmental correlation. A detailed explanation is provided in Supplementary Data Figure S3.
Table S6. Separate results of the bivariate SEM analysis for BP and its associated CpG sites in FTC and NTR
NTRFTC
Probeid Gene Trait P for dropping pathwaysP for dropping pathways
rg rerg re
 
 
  
Table S7. Phenotypes previously associated with the 34 CpG sites  
CpG sites Gene Phenotypes 
cg06500161 ABCG1 BMI, Lipid, Type 2 diabetes 
cg11468085 ALDH3B2 BMI 
cg00508575 ATP2B1 
 cg04583842 BANP BMI, CRP 
cg01820192 C21orf125 
 cg01343041 C2orf84 
 cg02003183 CDC42BPB CRP 
cg18119407 CFLAR BMI 
cg00574958 CPT1A BMI, lipids 
cg13696706 DAB2IP 
 cg19390658 GARS BMI 
cg21429551 GARS BMI 
cg00716257 JDP2 Alcohol 
cg05248321 KLHL33 CRP 
cg18120259 LOC100132354 BMI, A-diol 
cg12555233 MAN2A2 CRP 
cg14476101 PHGDH BMI, Lipids, A-diol 
cg16246545 PHGDH BMI, alcohol intake 
cg00008629 ROD1 Smoking 
cg02711608 SLC1A5 BMI, Lipids, CRP 
cg21766592 SLC1A5 BMI 
cg22304262 SLC1A5 BMI, A-diol 
cg11376147 SLC43A1 BMI 
cg06690548 SLC7A11 BMI, Lipids, A-diol 
cg07021906 SLC7A5 BMI, CRP 
cg07558761 SLC7A5 
 cg19695041 TACC1 
 cg19693031 TXNIP BMI, Lipids, Type 2 Diabetes 
cg08857797 VPS25 BMI 
cg24955196 ZBTB7B Alcohol 
cg26916780 ZNF609 
 cg12593793 Intergenic BMI 
cg18933331 Intergenic diabetes 
cg19266329 Intergenic Alcohol, All-cause mortality 
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Figure S6-A. cg14476101 and gene expression of PHGDH
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Figure S6-B. cg16246545 and gene expression of PHGDH
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Figure S6-C. cg06500161 and gene expression of ABCG1
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Figure S6-D. cg12593793 and gene expression of LMNA
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Figure S6-E. cg26916780 and gene expression of RBPMS2
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Figure S6F. cg02711608 and gene expression of SLC1A5
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